Skip to main content
EN ESPAÑOL
  • About Us
  • Local Resources
  • News & Events
  • Our Impact
  • Sign In
  • Understanding
Crohn’s & Colitis
    • Education
      • What is Crohn’s Disease?
      • What is Ulcerative Colitis?
      • Who Gets IBD?
      • IBD vs. IBS
      • Symptoms
      • Diagnosis & Testing
      • Treatment Options
    • Resources
      • Find a Medical Expert
      • IBD Medication Guide
      • GI Tract Guide
      • Financial Assistance Programs
      • Gut Friendly Recipes
      • Restroom Access App
    • About Our Research
      • Clinical Trials
      • Our Initiatives
    • Get Help
      • IBD Help Center
    • abc
      Newly Diagnosed
    • Awareness Week
      Awareness Week
  • Living with Crohn’s & Colitis
    • I need help with...
      • My new diagnosis
      • Affording care
      • Partnering with my doctor
      • Managing a flare
      • Starting a family
      • What should I eat?
      • IBD Help Center
      • MyIBD Learning
    • Health & Wellbeing
      • Managing Treatments
      • Beyond the Gut
      • Pain & Fatigue
      • Diet & Nutrition
      • Ostomy Care
      • Mental & Emotional Health
      • Screenings, Vaccines and More
      • Complications
      • Restroom Access
    • Support
      • Support Groups
      • Peer to Peer Mentoring
      • Camp Oasis for Kids
    • Communities
      • Parents, Kids & Teens
      • Local Chapters
      • Be an Advocate
      • Find an Event
      • Volunteer
  • Research
    • Clinical Programs
      • Quality of Care (QORUS)
      • Adult (SPARC IBD)
      • Children (CAPTURE)
      • Surgery (SIROC)
    • Research Funding
      • Flagship Awards
      • IBD Ventures Funding
      • Translational Research Awards
    • IBD Plexus
      • About IBD Plexus
      • Academic Success
    • Publications
      • Inflammatory Bowel Diseases
      • Crohn's & Colitis 360
      • Under the Microscope
    • lab
      Our Research Impact
    • doc
      Participate in Research
  • Healthcare
Professionals
    • For My Patient
      • Appeal Letters
      • Order Brochures
      • EMR Smart Phrases
      • Template for Section 504 Plan
      • Camp Oasis for Kids
      • IBD Help Center
      • MyIBD Learning
      • Quality of Care IBD Qorus
    • Education
      • IBP Pro Hub (Clinical Hub)
      • Online Modules & CME
      • Diet & Nutrition
      • Nurses & Advanced Practice
Providers
      • For Pharmacists
    • Resources
      • Health Maintenance Checklists
      • Position Papers
      • Downloadable Papers &
Brochures
      • Publications
    • Professional Membership
      • Information
      • Fellow of the Foundation
      • Join/Renew Membership
    • Opportunities
      • Career Development
      • Research Funding
      • Join a Committee
    • Meetings & Programs
      • Crohn’s & Colitis Congress
      • IBD Innovate
      • IBD Pro Programs
Get Involved
EN ESPAÑOL
  • About Us
  • Local Resources
  • News & Events
  • Our Impact
  • Sign In
Get Involved DONATE
    • General Information >>
    • Eligibility >>
    • Study Details >>
    • Contact Information >>

    A Phase 1 Study of Drug Interactions with a Study Drug for Inflammatory Conditions

    Published: 10/05/2021

    General Information:

    Sponsor
    Click Here to Learn More »
    Study Objective

    This is a clinical trial with healthy participants to:
    • see how the study drug is tolerated, if there are significant side effects, and how people feel after taking it when given with a single dose of another medication (drug B)
    • see if multiple doses of the study drug have an effect on the amount of drug B in your blood after a single dose 
    • measure how much of drug B is in your blood after you take a single dose  

    Phase of study
    Phase 1
    ⇧ RETURN TO TOP

    Eligibility:

    Age
    Adult (18+)
    Gender
    Female
    Male
    Disease Type
    other
    Severity
    Eligibility Criteria

    You may be eligible to participate if you are:
    ·    An adult age 18-65
    ·    In overall good health (do not have a current medical condition)
    ·    Willing to travel to our research facility in New Haven, CT
    There are other eligibility criteria for this study that will be discussed prior to your participation. These are assessed through a phone pre-screening and an in-person screening appointment, which is similar to a regular physical exam.

    ⇧ RETURN TO TOP

    Study Details:

    Study Description

    This is a Phase 1 study involving healthy volunteers to assess the effects of an investigational drug for inflammatory conditions, such as ulcerative colitis and Crohn's disease, when taken with an additional medication (drug B). It consists of up to 10 once-daily doses of the study drug and 2 doses of drug B, 15 consecutive overnight stays at our research facility, and 1 follow up phone call about 28-35 days after dosing. All of the doses are given by mouth. 


    Healthy volunteers are a vital part of clinical trials and help us to understand more about an investigational medicine before moving forward into later phases of drug development. Most treatments cannot be made available to patients without first being tested in healthy volunteers.

    Description of Treatment or Intervention (Mechanism of Action)

    The study drug works by inhibiting a type of enzyme in the body called a kinase. The inhibition of specific kinases can result in modulation of common cytokine pathways, which are normally associated with inflammation throughout the body. Therefore, by affecting these pathways, the study drug is being investigated as a potential treatment for inflammatory conditions such as ulcerative colitis (UC), Crohn's disease (CD), alopecia areata (AA), vitiligo, and rheumatoid arthritis (RA). 

    Patient Participation Requirements

    If this study may be a fit for you, you will be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing begins.


    If you choose to participate, you will be asked to stay at our facility for 15 consecutive nights. During your stay, you will receive up to 10 once-daily doses of the study drug and 2 doses of an additional medication to see if there is any effect when taken together. All doses are given orally (by mouth).


    Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood. All study procedures will be clearly explained to you during screening. 

    Possible Risks & Side Effects

    Taking part in this study has some risks. The study drug or procedure(s) may make you feel unwell or uncomfortable or could harm you. 


    In previous studies (156 people total), the study drug was generally well tolerated. However, the most commonly reported side effects in a study of patients with AA were: 


    ·    Headache  
    ·    Infections of the upper respiratory tract  
    ·    Acne  
    ·    Diarrhea  
    ·    Nausea  
    ·    Skin infections  


    These are not the only risks of participating in this study. All risks and side effects will be thoroughly covered during the informed consent process prior to any study participation. The informed consent document can also be downloaded online on our website. 

    Progress to Date

    The study drug has been studied in the following:  
    ·    Healthy participants (in single doses up to 800 mg and multiple doses up to 400 mg daily for 14 days)
    ·    Patients with RA (at the dose of 200 mg daily for 8 weeks) 
    ·    Patients with AA (at a starting dose of 200 mg daily for 4 weeks, followed by a maintenance dosing of 50 mg daily for 20 weeks)
    There are also ongoing studies of the study drug in patients with RA, UC, CD, AA, and vitiligo.

    ⇧ RETURN TO TOP

    Contact Information:

    Site Locations

    New Haven CRU Recruiting One Howe Street New Haven, Connecticut 06511
    203-401-0100
    [email protected]
    Click Here to Learn More »
    ⇧ RETURN TO TOP

    Crohn's & Colitis Foundation

    733 Third Avenue, Suite 510, New York NY 10017

    [email protected]
    • About Us
    • Sign In
    • Our Impact
    • Local Resources
    • Careers
    • News & Events
    • Store
    ©2026 Crohns & Colitis Foundation | The Crohn's & Colitis Foundation is a 501(c)(3) non-profit organization | EIN 13-6193105 Privacy Policy

    By using this website, you agree to our Terms of Use and to our Legal Notice and Privacy Policy. You also agree that any donation complies with Florida SB 700. This bill prohibits donations from “foreign countries of concern.” See our Donor Attestation Statement for more details.

    Charity Watch Top Rated Candid Platinum Transparency BBB Accredited Charity Charity Navigator